The kinase inhibitor fruquintinib offered improved outcomes vs placebo as a third- and fourth-line treatment in advanced non–small-cell lung cancer.
A large study found no association between the use of metformin or statins and the incidence of ovarian cancer in women with type 2 diabetes.
Lisinopril and carvedilol reduced cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines.
Substantial variation in treatment patterns can explain geographic differences in survival outcomes in patients with lung cancer, according to a UK study.
Some patients with HER2-positive breast cancer may develop an immunosuppressive phenotype based on an increase in regulatory T cells following treatment.
Alterations to DDR genes were associated with improved outcomes in patients with metastatic urothelial carcinoma who were treated with immunotherapy.
Vinflunine did not improve overall survival compared with physician’s choice of alkylating agent in patients with heavily pretreated metastatic breast cancer.
A meta-analysis was unable to find a conclusive relationship between physical activity and the risk of prostate cancer, though a reduced risk was suggested.
A large phase I trial offers further evidence that the anti–PD-L1 agent avelumab is generally well tolerated and results in relatively few serious adverse events.
Vemurafenib offered numerical improvement in disease-free survival in patients with resected melanoma, but the results did not reach statistical significance.